- Cello - the pharmaceutical and consumer strategic marketing group - posts headline pre-tax profits of £9.4m for the year to the end of December, up 9.9% on last time.

Revenue rose by 6.4% to £169.9m and gross profit is up 8.4% at £81.0m.

Headline basic earnings per share rose 12.3% to 8.14p (2013: 7.25p) while statutory basic earnings per share fell to 2.70p (2013: 4.41p). The full year dividend is up 15.6% to 2.60p (2013: 2.25p).

The group said a pre-tax provision had been made for a £2.1m VAT liability with HMRC. It said that considerable progress had been made in negotiations.

Chief executive Mark Scott said: "2014 was a critical year in establishing Cello Health as an integrated global player in the pharma space under a single brand and operating structure. We have been very pleased with the positive impact this has had on our ability to compete for and win large integrated contracts on a global scale. It also underpins our ability to continue our rapid expansion in the core US marketplace which is key to our growth strategy."

Story provided by